Related Experiment Video
Updated: Jul 19, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
[Effectiveness and safety of imatinib in seven gastrointestinal stromal tumor cases]
J Giménez Castellanos1, E Sánchez Gómez, J J Reina Zoiló
1Servicios de Farmacia Hospitalaria y Oncología Médica, Hospital Juan Ramón Jiménez, Huelva. figicas@ono.com
Objective:
To measure the effectiveness and safety of imatinib for gstrointestinal stromal tumors (GISTs).
Method:
A retrospective study from 1993 through June 2005 by identifying all patients diagnosed with GIST by the Pathology Department. The medical records of those treated with imatinib were reviewed. Demographic, diagnostic, therapeutic, and outcome-related data were collected.
Results:
Twenty-five patients were identified, 7 of them treated with imatinib. Total responses were 4/7; 2/7 cases were complete responses, and 2/7 were partial responses. Mean actuarial disease-free survival was 10 months, and overall survival was 44 months. Adverse reactions (ARs) reported included: 33% (5) gastrointestinal events, 40% (6) dermatologic events and/or edema, 14% (2) blood toxicity, and 13% (2) asthenia. In all, 2/7 patients experienced no imatinib-related toxicity.
Conclusions:
In our experience, imatinib is an effective, well tolerated therapy for malignant [c-Kit (CD117)-positive], non-resectable and/or metastatic GIST.
